*LIBTAYO was FDA approved in advanced CSCC in September 2018.1,4
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guidelines, go online to NCCN.org.
|Chapter 1||Dr Cohen's introduction and background on CSCC|
|Chapter 2||Overview of LIBTAYO|
|Chapter 3||LIBTAYO clinical trial designs for Study 1423 and Study 1540|
|Chapter 4||Efficacy results of LIBTAYO in advanced CSCC (time to response, objective response rate, duration of response)|
|Chapter 5||Safety profile of LIBTAYO in locally advanced CSCC|
|Chapter 6||Important Safety Information|
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC. 2. Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/study/NCT02760498. Updated January 26, 2021. Accessed March 24, 2021. 3. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months. Poster presented at: European Association of Dermato Oncology Congress 2021 Virtual Scientific Meeting. 15-17 April 2021. 4. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097. Updated June 25, 2020. Accessed January 19, 2021. 5. Data on file. Regeneron Pharmaceuticals, Inc. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Squamous Cell Skin Cancer V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 28, 2021. To view the most recent and complete version of the guidelines, go online to NCCN.org.